Prospective comparison of three guideline development methods for treatment of actinic keratosis

BMJ Quality and Safety

Volumn 20, Issue 10, 2011, Pages 832-841

  Borgonjen, Rinke Joachim ^a   Van Everdingen, Jannes J ^a   Bik, Cathelijne M ^a   Tuut, Mariska K ^b   Spuls, Phyllis I ^c   Van De Kerkhof, Peter C ^d  

^a Dutch Society of Dermatology and Venereology   (Netherlands)

^b PROVA ^*  (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; DICLOFENAC; FLUOROURACIL; GLYCOLIC ACID; IMIQUIMOD; NORDIHYDROGUAIARETIC ACID; RETINOID;

ACTINIC KERATOSIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; CURETTAGE; DERMATOLOGY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; EXCISION; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; INTERMETHOD COMPARISON; LOW LEVEL LASER THERAPY; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; SKIN ABRASION;

ADULT; CONSENSUS; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES;

EID: 80053252759     PISSN: 20445415     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmjqs.2010.050443     Document Type: Article

References (86)

1. Lebwohl M. Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol 2003;149:31-3. (Pubitemid 38064513)
2. Holmes C, Foley P, Freeman M, et al. Solar keratosis: epidemiology, pathogenesis, presentation and treatment. Australas J Dermatol 2007;48:67-74.
3. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42:4-7.
4. Dutch Clinical Practice Guideline Actinic Keratosis. http://www. huidarts.info/documents/?v=2&id=193 (accessed 24 Nov 2010).
5. Grimshaw J, Russel I. Achieving health gain through clinical guidelines: current activities and future directions. Ann Intern Med 1990;113:709-14.
6. Burgers JS, Grol R, Klazinga NS, et al. Towards evidence-based clinical practice: an international survey of 18 clinical guideline programs. Int J Qual Health Care 2003;15:31-45. (Pubitemid 36305560)
7. Quaedvlieg PFJ, Ostertag JU, De Kort JML, et al. Evidence based treatments of actinic keratoses: a systematic review of efficacy. J Dermatol Treat. In press.
8. Coleman WP III, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. J Dermatol Surg 1996;22:17-21. (Pubitemid 26038730)
9. Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. Plast Reconstr Surg 1987;80:47-54. (Pubitemid 17158558)
10. Zouboulis CC, Rohrs H. Kryochirurgische behandlung aktinischer keratosen mit evidenzbasierter ubersicht. Hautarzt 2006;56:353-8.
11. Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006;155:1029-36. (Pubitemid 44564515)
12. Krawtchenko N, Roewert HJ, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J of Dermatol 2007;157(Suppl 2):34-40. (Pubitemid 350179628)
13. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:258-62.
14. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003;14:99-106. (Pubitemid 36648700)
15. Szeimies RM, Radakovic S, Calzavara-Pinton PG, et al. A prospective, randomized study comparing photodynamic therapy with Metvix® to cryotherapy in actinic keratoses. J Eur Acad Dermatol Venereol 2000;14:235.
16. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004;151:196-200. (Pubitemid 39061299)
17. Gilbert DJ. Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy. J Drugs Dermatol 2005;4:161-3.
18. De Haas ER, De Vijlder HC, Sterenborg HJ, et al. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2008;22:426-30. (Pubitemid 351436911)
19. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 2001;45:96-104. (Pubitemid 32655701)
20. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003;48:227-32. (Pubitemid 36232321)
21. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004;140:41-6. (Pubitemid 38090269)
22. Smith S, Piacquadio D, Morhenn V, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003;2:629-35.
23. Tarstedt M, Rosdahl I, Berne B, et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005;85:424-8. (Pubitemid 41345617)
24. Touma D, Yaar M, Whitehead S, et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004;140:33-40. (Pubitemid 38090268)
25. Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol 2006;155:1262-9. (Pubitemid 44730005)
26. Varma S, Wilson H, Kurwa HA, et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001;144:567-74. (Pubitemid 32232013)
27. Wiegell SR, Haedersdal M, Philipsen PA, et al. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol 2008;158:740-6. (Pubitemid 351415748)
28. Zelickson B, Counters J, Coles C, et al. Light patch: preliminary report of a novel form of blue light delivery for the treatment of actinic keratosis. Dermatol Surg 2005;31:375-8. (Pubitemid 43073003)
29. Iyer S, Friedli A, Bowes L, et al. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med 2004;34:114-19. (Pubitemid 38326354)
30. Jiang SB, Levine VJ, Nehal KS, et al. Er:YAG laser for the treatment of actinic keratoses. Dermatol Surg 2000;26:437-40. (Pubitemid 30305322)
31. Wollina U, Konrad H, Karamfilov T. Treatment of common warts and actinic keratoses by Er:YAG laser. J Cutan Laser Ther 2001;3:63-6. (Pubitemid 34112670)
32. Ostertag JU, Quaedvlieg PJF, van der Geer S, et al. A clinical comparison and long term follow up of topical 5-FU versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med 2006;38:731-9. (Pubitemid 44522028)
33. Ostertag JU, Quaedvlieg PJ, Neumann MH, et al. Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp. Dermatol Surg 2006;32:261-7.
34. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995;131:176-81.
35. Marrero GM, Katz BE. The new fluor-hydroxy pulse peel. A combination of 5-fluorouracil and glycolic acid. Dermatol Surg 1998;24:973-8. (Pubitemid 28453045)
36. Witheiler DD, Lawrence N, Cox SE, et al. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg 1997;23:191-6. (Pubitemid 27200625)
37. Epstein E. Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol 1998;38:77-80. (Pubitemid 28100469)
38. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9:209-14. (Pubitemid 44265792)
39. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002;70:335-9. (Pubitemid 41757441)
40. Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 2004;140:813-16. (Pubitemid 38917849)
41. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002;24:990-1000. (Pubitemid 34734743)
42. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002;70:22-9.
43. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007;157:133-41. (Pubitemid 46934262)
44. Chen K, Yap LM, Marks R, et al. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol 2003;44:250-5. (Pubitemid 37518550)
45. Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol 2006;55:537-8. (Pubitemid 44189601)
46. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005;141:467-73. (Pubitemid 40547405)
47. Kose O, Koc E, Erbil AH, et al. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat 2008;19:159-63. (Pubitemid 351882995)
48. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21. (Pubitemid 38580548)
49. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, doubleblind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498-502. (Pubitemid 35315741)
50. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547-55. (Pubitemid 39278073)
51. Torres A, Storey L, Anders M, et al. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod. Br J Dermatol 2007;157:1132-47. (Pubitemid 350115691)
52. Vender RB, Goldberg O. Innovative uses of imiquimod. J Drugs Dermatol 2005;4:58-63.
53. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006;126:1251-5. (Pubitemid 43997904)
54. Fariba I, Ali A, Hossein SA, et al. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venereol Leprol 2006;72:346-9. (Pubitemid 44579162)
55. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003;44:40-3. (Pubitemid 36246421)
56. McEwan LE, Smith JG. Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Australas J Dermatol 1997;38:187-9.
57. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002;146:94-100. (Pubitemid 34158414)
58. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5- fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006;5:156-9.
59. Wolf JE Jr, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001;40:709-13.
60. Alirezai M, Dupuy P, Amblard P, et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dermatol 1994;30:447-51. (Pubitemid 24129437)
61. Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol 2003;49:83-9.
62. Moriarty M, Dunn J, Darragh A, et al. Etretinate in treatment of actinic keratosis. A double-blind crossover study. Lancet 1982;1:364-5. (Pubitemid 12214762)
63. De Sévaux RG, Smit JV, De Jong EM, et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003;49:407-12. (Pubitemid 37051901)
64. Akar A, Bülent Taştan H, Erbil H, et al. Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses. J Dermatol Treat 2001;12:199-203. (Pubitemid 34033263)
65. Grimaître M, Etienne A, Fathi M, et al. Topical colchicine therapy for actinic keratoses. Dermatology 2000;200:346-8. (Pubitemid 30451591)
66. Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991;24:738-43.
67. Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000;9:1281-6. (Pubitemid 32044795)
68. Cafardi JA, Elmets CA. T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther 2008;8:829-38. (Pubitemid 351860212)
69. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006;16:335-9. (Pubitemid 44328971)
70. Lomotan EA, Michel G, Lin Z, et al. How "should" we write guideline recommendations? Interpretation of deontic terminology in clinical practice guidelines: survey of the health services community. Qual Saf Health Care. Published Online First: 10 August 2010. doi:10.1136/qshc.2009.032565.
71. Dutch CBO Guideline Manual. http://www.cbo.nl/thema/Richtlijnen/ EBRO-handleiding/6-Schrijven-van-teksten/#6.4 (accessed 24 Nov 2010).
72. Wakkee M, Lugtenberg M, Spuls PI, et al. Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists. Br J Dermatol 2008;159:426-32. (Pubitemid 352009873)
73. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65. (Pubitemid 29493800)
74. Grol R, Grimshaw J. Evidence-based implementation of evidence-based medicine. Jt Comm J Qual Improv 1999;25:503-10.
75. Berker de D, McGregor JM, Hughes BR, et al. Guidelines for the management of actinic keratoses. Br J Dermatol 2007;156:222-30.
76. Braathen LD, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. J Am Acad Dermatol 2007;56:125-43. (Pubitemid 44969292)
77. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006;16:599-606.
78. Franke RH, Kaul JD. The Hawthorne experiments: first statistical interpretation. Am Sociol Rev 1978;43:623-43.
79. Raine R, Sanderson C, Black N. Developing clinical guidelines: a challenge to current methods. BMJ 2005;331:631-3. (Pubitemid 41360784)
80. West S, King V, Carey TS, et al. Systems to rate the strength of scientific evidence. Evid Rep Technol Assess (Summ) 2002;47:1-11.
81. Cluzeau FA, Burgers JS, Brouwers M, et al. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12:18-23. (Pubitemid 36241251)
82. http://www.g-i-n.net/ (accessed 24 Nov 2010).
83. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. (Pubitemid 351632017)
84. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008;336:1049-51. Erratum in: BMJ. 2008;336(7658).
85. Shiffman RN, Dixon J, Brandt C, et al. The GuideLine Implementability Appraisal (GLIA): development of an instrument to identify obstacles to guideline implementation. BMC Med Inform Decis Mak 2005;5:23.
86. Fervers B, Burgers JS, Voellinger R, et al. Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation.BMJ Qual Saf 2011;20:228-36.